Imaging-based biomarkers such as perfusion magnetic resonance imaging, already used to assess treatment response in gliomas (111), could be integrated with molecular readouts (e.g., NF2/hippo status) for multimodal profiling. The gene discussed is NF2; the disease is central nervous system cancer.